This study investigates KRAS G12D-mutant solid tumors. It looks at how the investigational medication works alone and with other chemotherapy medicines.
The study evaluates safety and how well the investigational medication works against the tumors.
- Who can participate: Participants must have advanced cancer with a KRAS G12D mutation and have undergone at least one prior treatment with a good performance status.
- Study details: Participants will take the investigational medication alone or with chemotherapy.
- Study timelines: The study will last approximately 5 years.